Preclinical models have been developed and applied to predict the clinical efficacy of immune checkpoint antibodies. Now these models can be used to dissect the mechanisms by which such immunotherapeutic antibodies work and to build the rationale for combining immune checkpoint-targeting antibodies with potential synergistic activity in cancer patients.
View details for DOI 10.4161/21624011.2014.954869
View details for PubMedID 25610751
View details for PubMedCentralID PMC4292403